Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 21.69
(-2.58%)
USD 21.69
(-2.58%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -175.67 Million USD | -5.41% |
| 2022 | -162.28 Million USD | -26.81% |
| 2021 | -132.58 Million USD | -61.4% |
| 2020 | -87.21 Million USD | -232.89% |
| 2019 | 65.62 Million USD | 227.02% |
| 2018 | -51.23 Million USD | -55.65% |
| 2017 | -29.68 Million USD | 55.19% |
| 2016 | -78.46 Million USD | 23.25% |
| 2015 | -89.6 Million USD | -132.63% |
| 2014 | -47.38 Million USD | -179.51% |
| 2013 | -20.1 Million USD | 19.86% |
| 2012 | -19.34 Million USD | -73.37% |
| 2011 | -8.51 Million USD | -8.66% |
| 2010 | -6.68 Million USD | 47.78% |
| 2009 | -18.16 Million USD | 44.4% |
| 2008 | -33.24 Million USD | 8.33% |
| 2007 | -35.68 Million USD | -87.82% |
| 2006 | -19.42 Million USD | -77.31% |
| 2005 | -8.94 Million USD | -313.63% |
| 2004 | -2.67 Million USD | -2742.71% |
| 2003 | -94.34 Thousand USD | 93.54% |
| 2002 | -1.4 Million USD | -795.53% |
| 2001 | -102.73 Thousand USD | 16.61% |
| 2000 | -101.61 Thousand USD | -223.35% |
| 1999 | -48.09 Thousand USD | 384.26% |
| 1998 | -15.11 Thousand USD | -108.7% |
| 1997 | -54.83 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -171.35 Million USD | -42.42% |
| 2024 Q1 | -129.05 Million USD | -29.23% |
| 2024 Q2 | -121.66 Million USD | 10.72% |
| 2023 Q1 | -42.13 Million USD | 49.74% |
| 2023 Q2 | 55.4 Million USD | 231.49% |
| 2023 Q4 | -99.86 Million USD | -5.18% |
| 2023 FY | - USD | -5.41% |
| 2023 Q3 | -94.94 Million USD | -271.38% |
| 2022 Q4 | -83.83 Million USD | -19.22% |
| 2022 Q2 | 44.14 Million USD | 172.67% |
| 2022 Q1 | -60.74 Million USD | 2.61% |
| 2022 FY | - USD | -26.81% |
| 2022 Q3 | -70.31 Million USD | -259.27% |
| 2021 Q4 | -62.37 Million USD | -108.83% |
| 2021 FY | - USD | -61.4% |
| 2021 Q1 | -22.2 Million USD | 54.07% |
| 2021 Q2 | -26.31 Million USD | -18.5% |
| 2021 Q3 | -29.87 Million USD | -13.52% |
| 2020 Q3 | -14.4 Million USD | 30.95% |
| 2020 Q4 | -48.34 Million USD | -235.51% |
| 2020 Q2 | -20.86 Million USD | -480.79% |
| 2020 FY | - USD | -232.89% |
| 2020 Q1 | -3.59 Million USD | -133.52% |
| 2019 Q1 | 12.12 Million USD | 221.96% |
| 2019 Q3 | 19.59 Million USD | -15.47% |
| 2019 Q4 | 10.72 Million USD | -45.3% |
| 2019 Q2 | 23.18 Million USD | 91.26% |
| 2019 FY | - USD | 227.02% |
| 2018 Q3 | -14.74 Million USD | -6.36% |
| 2018 FY | - USD | -55.65% |
| 2018 Q4 | -9.94 Million USD | 32.58% |
| 2018 Q2 | -13.86 Million USD | -5.63% |
| 2018 Q1 | -13.12 Million USD | -55.0% |
| 2017 Q1 | -15.2 Million USD | 6.84% |
| 2017 FY | - USD | 55.19% |
| 2017 Q2 | -4.91 Million USD | 67.67% |
| 2017 Q4 | -8.46 Million USD | -83.47% |
| 2017 Q3 | -4.61 Million USD | 6.11% |
| 2016 Q3 | -18.4 Million USD | 11.62% |
| 2016 Q2 | -20.83 Million USD | -12.46% |
| 2016 Q4 | -16.31 Million USD | 11.37% |
| 2016 FY | - USD | 23.25% |
| 2016 Q1 | -18.52 Million USD | 25.3% |
| 2015 Q4 | -24.79 Million USD | -63.7% |
| 2015 FY | - USD | -132.63% |
| 2015 Q3 | -15.14 Million USD | 48.47% |
| 2015 Q2 | -29.39 Million USD | -8.16% |
| 2015 Q1 | -27.18 Million USD | -56.05% |
| 2014 Q1 | -3.03 Million USD | -45.52% |
| 2014 Q4 | -17.41 Million USD | -32.13% |
| 2014 Q3 | -13.18 Million USD | -67.71% |
| 2014 Q2 | -7.86 Million USD | -159.17% |
| 2014 FY | - USD | -179.51% |
| 2013 Q1 | -4.42 Million USD | 6.59% |
| 2013 Q2 | -4.85 Million USD | -9.81% |
| 2013 Q3 | -3.48 Million USD | 28.34% |
| 2013 Q4 | -2.08 Million USD | 40.12% |
| 2013 FY | - USD | 19.86% |
| 2012 Q1 | -5.03 Million USD | -75.77% |
| 2012 FY | - USD | -73.37% |
| 2012 Q4 | -4.73 Million USD | 4.59% |
| 2012 Q3 | -4.96 Million USD | -30.97% |
| 2012 Q2 | -3.78 Million USD | 24.75% |
| 2011 FY | - USD | -8.66% |
| 2011 Q1 | -1.4 Million USD | 38.27% |
| 2011 Q2 | -2.14 Million USD | -53.05% |
| 2011 Q3 | -1.58 Million USD | 26.08% |
| 2011 Q4 | -2.86 Million USD | -80.75% |
| 2010 Q3 | -3.56 Million USD | -77.64% |
| 2010 Q4 | -2.26 Million USD | 36.4% |
| 2010 FY | - USD | 47.78% |
| 2010 Q1 | -1.98 Million USD | 27.36% |
| 2010 Q2 | -2 Million USD | -1.14% |
| 2009 FY | - USD | 44.4% |
| 2009 Q4 | -2.73 Million USD | -38.09% |
| 2009 Q1 | -9.01 Million USD | 20.02% |
| 2009 Q2 | -5.02 Million USD | 44.23% |
| 2009 Q3 | -1.98 Million USD | 60.63% |
| 2008 Q4 | -11.27 Million USD | -17.09% |
| 2008 Q3 | -9.62 Million USD | -42.13% |
| 2008 Q2 | -6.77 Million USD | -2.66% |
| 2008 Q1 | -6.59 Million USD | 41.88% |
| 2008 FY | - USD | 8.33% |
| 2007 Q2 | -8.19 Million USD | -93.22% |
| 2007 Q1 | -4.24 Million USD | 43.9% |
| 2007 FY | - USD | -87.82% |
| 2007 Q4 | -11.35 Million USD | 13.61% |
| 2007 Q3 | -13.14 Million USD | -60.33% |
| 2006 FY | - USD | -77.31% |
| 2006 Q3 | -4.37 Million USD | -12.22% |
| 2006 Q1 | -3.82 Million USD | -108.72% |
| 2006 Q2 | -3.9 Million USD | -1.93% |
| 2006 Q4 | -7.56 Million USD | -72.75% |
| 2005 Q3 | -3.16 Million USD | 24.45% |
| 2005 Q2 | -4.18 Million USD | -114.8% |
| 2005 Q1 | -1.94 Million USD | -58.96% |
| 2005 FY | - USD | -313.63% |
| 2005 Q4 | -1.83 Million USD | 42.01% |
| 2004 Q2 | -799.08 Thousand USD | -902.22% |
| 2004 Q4 | -1.22 Million USD | -146.35% |
| 2004 Q1 | -79.73 Thousand USD | -352.92% |
| 2004 FY | - USD | -2742.71% |
| 2004 Q3 | -497.56 Thousand USD | 37.73% |
| 2003 Q3 | -13.39 Thousand USD | 52.68% |
| 2003 Q1 | -30.56 Thousand USD | 97.68% |
| 2003 FY | - USD | 93.54% |
| 2003 Q4 | 71.72 Thousand USD | -30.57% |
| 2003 Q2 | -27.76 Thousand USD | 6.77% |
| 2002 Q1 | -25.7 Thousand USD | 26.43% |
| 2002 FY | - USD | -795.53% |
| 2002 Q4 | -1.31 Million USD | -2710.05% |
| 2002 Q3 | -43.86 Thousand USD | 34.64% |
| 2002 Q2 | -22.36 Thousand USD | -173.08% |
| 2001 Q4 | -29.86 Thousand USD | -5.43% |
| 2001 FY | - USD | 16.61% |
| 2001 Q2 | -23.75 Thousand USD | 46.91% |
| 2001 Q1 | -33.01 Thousand USD | 48.56% |
| 2001 Q3 | -33.8 Thousand USD | -4.86% |
| 2000 Q1 | -30.85 Thousand USD | 60.19% |
| 2000 FY | - USD | -223.35% |
| 2000 Q4 | -26.22 Thousand USD | -448.87% |
| 2000 Q2 | -23.43 Thousand USD | 24.43% |
| 2000 Q3 | -21.1 Thousand USD | 10.62% |
| 1999 Q3 | 620 Thousand USD | 2166.67% |
| 1999 FY | - USD | 384.26% |
| 1999 Q2 | -30 Thousand USD | 0.0% |
| 1999 Q1 | -30 Thousand USD | 0.0% |
| 1999 Q4 | -80 Thousand USD | -112.9% |
| 1998 Q2 | -20 Thousand USD | 0.0% |
| 1998 FY | - USD | -108.7% |
| 1998 Q3 | -10 Thousand USD | 50.0% |
| 1998 Q4 | -30 Thousand USD | -200.0% |
| 1997 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -640.139% |
| Codexis, Inc. | -49.28 Million USD | -256.456% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 25.107% |
| Organovo Holdings, Inc. | -14.8 Million USD | -1086.492% |